GeoVax Labs Net Income 2006-2021 | GOVX

GeoVax Labs net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
GeoVax Labs Annual Net Income
(Millions of US $)
2020 $-3
2019 $-2
2018 $-3
2017 $-2
2016 $-3
2015 $-3
2014 $-3
2013 $-2
2012 $-2
2011 $-2
2010 $-3
2009 $-3
2008 $-4
2007 $-4
2006 $-1
2005 $-2
GeoVax Labs Quarterly Net Income
(Millions of US $)
2021-06-30 $-1
2021-03-31 $-2
2020-12-31 $-1
2020-09-30 $-1
2020-06-30 $-0
2020-03-31 $-1
2019-12-31 $-1
2019-09-30 $-0
2019-06-30 $-1
2019-03-31 $-1
2018-12-31 $-1
2018-09-30 $-1
2018-06-30 $-1
2018-03-31 $-1
2017-12-31 $-1
2017-09-30 $-1
2017-06-30 $-1
2017-03-31 $-1
2016-12-31 $-1
2016-09-30 $-0
2016-06-30 $-1
2016-03-31 $-1
2015-12-31 $-1
2015-09-30 $-1
2015-06-30 $-1
2015-03-31 $-1
2014-12-31 $-1
2014-09-30 $-1
2014-06-30 $-1
2014-03-31 $-1
2013-12-31 $-1
2013-09-30 $-0
2013-06-30 $-1
2013-03-31 $-1
2012-12-31 $-1
2012-09-30 $-0
2012-06-30 $-0
2012-03-31 $-1
2011-12-31 $-1
2011-09-30 $-0
2011-06-30 $-0
2011-03-31 $-1
2010-12-31 $-0
2010-09-30 $-1
2010-06-30 $-1
2010-03-31 $-1
2009-12-31 $-1
2009-09-30 $-0
2009-06-30 $-1
2009-03-31 $-1
2008-12-31 $-1
2008-09-30 $-1
2008-06-30 $-1
2008-03-31 $-1
2007-12-31 $-1
2007-09-30 $-1
2007-06-30 $-1
2007-03-31 $-1
2006-12-31 $-0
2006-09-30 $-0
2006-06-30 $0
2006-03-31 $-0
2005-12-31 $-1
2005-09-30 $-0
2005-06-30 $-0
2005-03-31 $-0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.024B $0.002B
GeoVax Labs Inc. is a clinical-stage biotechnology company. It engages in developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle based vaccine platform. GeoVax Labs Inc. is based in ATLANTA, GA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76